Molecular imaging enables the search for a different kind of discovery. The kind that has the ability to have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.
The search for true discovery is unique. It requires the right balance of technology and people. The technology to enable the search and the people to embrace it. People open to opportunity, who persistently look for a better way to do something. To continuously improve the world around them. The kind of person that embodies the spirit of discovery.
We collaborate every day with the great minds working in molecular imaging. It is through these partnerships that we recognize your ambition. We see your attempts to diagnose and stage disease earlier to improve patient outcomes. We know firsthand of your desire to conduct exciting research such as simultaneous dual-isotope studies so you can expand the reach of nuclear medicine's impact. And we realize you are continually trying to provide the most comfortable experience possible for your patients.
We share in your drive to make things better. It's why, for the past 60 years, we have stayed committed to developing the potential of nuclear medicine. And it's what led us to the breakthrough CZT technology. Not every technological innovation has the ability to transform how we see and understand the world around us. CZT does. Its revolutionary detection capability is not only transforming our understanding of disease at the cellular level, it's even being used to record events at the astronomical level.
Introducing DiscoveryTM NM/CT 670 CZT, the first commercially-available general purpose SPECT/CT system powered by CZT technology. Help bring your theories to life with a system designed to leverage all that CZT can do. Engineered for improvements in lesion detection1, image quality and patient comfort and combined with advanced quantitative applications provided through XelerisTM, this system renews the promise of nuclear medicine's potential for true discovery.
We have always believed in the potential of nuclear medicine. Every innovation has been a step forward in delivering more accuracy, more consistency, more personalization and more value to you. Now, with CZT technology, it's time to break through to a whole new level of capability for research and clinical performance.
CZT is the key component to the future of nuclear medicine. Not only is it lighter and more compact than the Nal crystals used in analog technology. It is pixelated. Housed within smaller and sleeker 39 cm x 51 cm FOV Planar and SPECT detector heads, each individual detector is like the eye of a fly, with thousands of tiny 2.46 mm sized detectors working together to capture more events, more accurately. It also enables direct conversion. With CZT, each photon is directly converted into an electrical signal that accurately identifies its location and energy. This eliminates the signal loss and noise inherent in conventional SPECT/CT detection technology, recovering lost spatial and energy resolution.
Discovery NM/CT 670 CZT is the first general purpose system designed with this breakthrough detection technology. Combined with registered collimation to deliver higher resolution images, edge-to-edge performance allowing for more comfortable positioning of your patients and the latest in advanced quantitative applications provided by Xeleris, this system is capable of transforming the entire nuclear medicine experience.
As molecular imaging continues to move toward the development of disease specific diagnoses and increasingly personalized care, clinicians are looking for technology that will get them there. For nuclear medicine, resolution is important. Early disease detection is only possible with a high system resolution that enables visualization of finer anatomic detail. In addition, research with multi-isotope exams requires precise energy resolution to reduce spillover between tracers.
With direct conversion detection, Discovery NM/CT 670 CZT has substantially improved system resolution by eliminating the signal loss and noise that comes with analog detection technology. It also uses a registered collimation design that aligns each collimator with a single detector pixel. This design eliminates the impact of collimator resolution that would normally effect the overall system resolution. The result is an improved contrast-to-noise ratio and spatial resolution down to 2.5 mm.
CZT can also simultaneously detect the energy from multiple tracers with more definition than conventional technology. Its 6.3 percent energy resolution makes it possible to explore new protocols with the variety of SPECT tracers available.
Often times, the technology needed to produce a specific result has an impact on the overall experience of getting that result. Many consumer industries have had to work around the design constraints that come with analog technology. For nuclear medicine, the crystal and photomultiplier tubes have to overlap beyond the useful field of view in order to limit image degradation at the edges. This creates a significant amount of unusable dead space at the edge of the detector making some procedures difficult, at times impossible, for patients to physically endure.
With a patient-centric design, certain exams become tolerable. One such exam is a cardiac SPECT scan requiring patients to extend and hold their arms above their head for a long duration. Also, more exams become available, such as whole-body procedures for taller patients and gurney scans for larger patients.
Just like the transition from analog to digital technology in other industries, the technology required to create a digital image is lighter, and more compact, with looser constraints on system design. Using registered collimation, Discovery NM/CT 670 CZT contains detected events entirely within a single pixel aligned to one collimator hole, even at the outermost edges of the FOV. This reduction in dead space enables a system design that can get closer to anatomies and increase patient comfort.
The applications you use to interpret and communicate molecular information are just as important as the tracers used to highlight that information and the technology used to capture it.
Quantitative applications allow you to prove what you see and, more importantly, prove what can't be seen. They give you the assurance to determine the best course of treatment and the confidence to adapt treatment. They also give you the information to build a database of accurate results. Results that can be used to better inform the decisions you make for each patient and also, to inform the research that will develop more specific indications for disease.
Xeleris is our proven workstation dedicated to nuclear medicine. In the past, Xeleris led the way with mobilized applications that gave you accessible, easy-to-use tools to enhance productivity. Now, our latest version of Xeleris is leading the way with modern, quantitative applications for nuclear medicine; applications that help give you greater confidence of absolute quantitation in customizable, easy-to-read reports across multiple care areas. with modern, quantitative applications for nuclear medicine; applications that give you the certainty of absolute quantitation in customizable, easy-to-read reports across multiple care areas.